1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Elucidating the Key Components of the Therapeutic Effects of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Optional) is sponsored by National Institute of Mental Health (NIMH). The purpose of this notice of funding opportunity (NOFO) is to elucidate the key components of the therapeutic effects of rapid-acting psychotropic interventional drugs (RAPIDs) by addressing the methodological challenges involved with these clinical trials.
Get alerted about grants like this
Save a search for “National Institute of Mental Health (NIMH)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required) Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required) Agency: National Institutes of Health Assistance Listings: 93. 242 -- Mental Health Research Grants 93.
279 -- Drug Use and Addiction Research Programs Last Updated: May 13, 2026 View version history on Grants. gov The purpose of this notice of funding opportunity (NOFO) is to elucidate the key components of the therapeutic effects of rapid-acting psychotropic interventional drugs (RAPIDs) by addressing the methodological challenges involved with these clinical trials.
In addition, this NOFO seeks to advance understanding of how RAPIDs and adjunctive psychosocial interventions can be optimally delivered, monitored, and sustained over time to enhance effectiveness and generalizability. The NOFO will support studies designed to enhance the rigor of RAPID clinical trial design, which will ultimately increase the interpretability of the data and the generalizability of the results.
City or township governments Federally recognized Native American tribal governments Public and Indian housing authorities Special district governments For-profit organizations other than small businesses Private institutions of higher education Public and state institutions of higher education Independent school districts Nonprofits non-higher education without 501(c)(3) Nonprofits non-higher education with 501(c)(3) Other Native American tribal organizations Refer to Section III.
Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. Grantor contact information Division of Translational Research DTRcommunications@nih. gov DTRcommunications@nih.
gov DTRcommunications@nih. gov File name Description Last updated RFA-MH-27-135-Revised-Full-Announcement. html RFA-MH-27-135-Revised-Full-Announcement.
html Apr 29, 2026 05:35 PM UTC Link to additional information Closing: October 11, 2026 Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Non-domestic (non-U. S.) Entities (Foreign Organizations) are not eligible to apply. Confirm the full requirements in the official notice before applying.
Applications for Elucidating the Key Components of the Therapeutic Effects of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Optional) are due October 11, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Elucidating the Key Components of the Therapeutic Effects of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Optional) is funded by National Institute of Mental Health (NIMH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Standardizing Data and Metadata from Wearable Devices (R01 Clinical Trial Not Allowed) is sponsored by National Institute of Mental Health (NIMH). This funding opportunity supports the creation of standards for data and metadata from wearable devices and cell phones to promote re-use and integration of this data by researchers. The goal is to facilitate secondary data analysis and the development of software packages and workflows, which is crucial for advancing health equity research using wearable data. Applicants are expected to partner with device manufacturers and the research community.
NIH Research Education Program (R25) is sponsored by National Institute of Mental Health (NIMH). This program supports creative and innovative research education programs that foster the development of mental health researchers. While often for institutions, specific R25 programs can be open to individuals, including early-career investigators interested in becoming mental health researchers.
Tennessee's $206.9M RHTP allocation begins distribution with a 30-day virtual maternal/child mental health consultation grant. The state plans a new opportunity every Friday — the cadence and structure here are the blueprint for how the $50B nationwide program rolls out.
Read articleThe April 18 executive order, ARPA-H EVIDENT initiative, and FDA priority vouchers are reshaping mental health research funding. A guide for grant seekers.
Read articleHHS launched the STREETS Initiative and SAMHSA announced $69M in mental health grants as part of the Great American Recovery. A deep analysis of eligibility, strategy, and what organizations should apply.
Read article